ProfileGDS5678 / 1448353_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 97% 96% 97% 97% 96% 97% 97% 97% 97% 97% 97% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.0374596
GSM967853U87-EV human glioblastoma xenograft - Control 29.2489497
GSM967854U87-EV human glioblastoma xenograft - Control 39.1217696
GSM967855U87-EV human glioblastoma xenograft - Control 49.3047697
GSM967856U87-EV human glioblastoma xenograft - Control 59.439697
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.8186196
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.0200797
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.2459197
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.3888797
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.3198497
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.2689597
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.3297697
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.5289297
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.2550997